Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer

Yang, JP; Han, JQ; Zhang, YL; Muhetaer, M; Chen, NY; Yan, X

Yan, X (通讯作者)，Sichuan Univ, West China Hosp, Canc Ctr, Dept Head Neck & Mammary Gland Oncol, Chengdu, Peoples R China.;Yan, X (通讯作者)，Sichuan Univ, West China Hosp, Clin Res Ctr Breast, Chengdu, Peoples R China.

FRONTIERS IN PHARMACOLOGY, 2022; 13 ():

Abstract

Background: The DESTINY-Breast03 clinical trial demonstrated that trastuzumab deruxtecan (T-DXd) outperformed trastuzumab emtansine (T-DM1) in progres......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索